CoChat
Sign Up
Cited by 615Nanoparticle-Based Drug DeliveryAdvanced Drug Delivery SystemsAdvancements in Transdermal Drug Delivery

Potential of solid lipid nanoparticles in brain targeting.

Kaur, Indu Pal, Bhandari, Rohit, Bhandari, Swati, Kakkar, Vandita·2008·Journal of Controlled Release
DOI 10.1016/j.jconrel.2007.12.018
Open this paper in CoChat — free account

Abstract

Brain is a delicate organ, isolated from general circulation and characterized by the presence of relatively impermeable endothelial cells with tight junctions, enzymatic activity and the presence of active efflux transporter mechanisms (like P-gp efflux). These formidable obstacles often impede drug delivery to the brain. As a result several promising molecules (showing a good potential in in vitro evaluation) are lost from the market for a mere consequence of lack of in vivo response probably because the molecule cannot reach the brain in a sufficient concentration. The options to tailor make molecules for brain, though open to the medical chemist, are a costly proposition in terms of money, manpower and time (almost 50 years). The premedial existing approaches for brain delivery like superficial and ventricular application of chemical or the application of chemicals to brain parenchyma are invasive and hence are less patient friendly, more laborious and require skill and could also damage the brain permanently. In view of these considerations novel drug delivery systems such as the nanoparticles are presently being explored for their suitability for targeted brain delivery. Nanoparticles are solid colloidal particles ranging in size from 1 to 1000 nm (<1 microm) and composed of macromolecular material. Nanoparticles could be polymeric or lipidic (SLNs). SLNs are taken up readily by the brain because of their lipidic nature. The bioacceptable and biodegradable nature of SLNs makes them less toxic as compared to polymeric nanoparticles. Supplemented with small size which prolongs the circulation time in blood, feasible scale up for large scale production and absence of burst effect makes them interesting candidates for study. In the present review we will discuss about the barriers to CNS drug delivery, strategies to bypass the blood-brain barrier and characterization methods of SLNs and their usefulness. The proposed mechanism of uptake, methods of prolonging the plasma retention and the in vivo and in vitro methods for assessment will also be discussed in some details.

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2007.12.018

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the last few decades, nanomedicines have shown great potential toward CNS drug delivery owing to their nanosize range, unique physicochemical properties, and ability to exploit surface-engineered biocompatible and biodegradable nanomaterials.

    “In the last few decades, nanomedicines have shown great potential toward CNS drug delivery owing to its nanosize range, their unique physic-chemical properties and ability to exploit surface engineered biocompatible and biodegradable nanomaterials (Kaur et al., 2008).”

    From Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs (2020) · cites this paper as Kaur et al., 2008

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V.
Affiliations
Panjab University (IN)
Corresponding author
Kaur, Indu Pal
ORCID
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2008-04
Volume
127
Issue
2
Pages
97-109
ISSN
0168-3659 (ISSN-L)
DOI
10.1016/j.jconrel.2007.12.018
OpenAlex
W2086626740
Cited by
615
References
100
Citations by year
2026: 16 · 2025: 26 · 2024: 39 · 2023: 43 · 2022: 41 · 2021: 51 · 2020: 38 · 2019: 28 · 2018: 41 · 2017: 36 · 2016: 33 · 2015: 27 · 2014: 36 · 2013: 47 · 2012: 37
FWCI
1.18
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Controlled Release (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
Keywords
solid lipid nanoparticles, brain drug delivery, blood-brain barrier, P-glycoprotein efflux, tight junctions, nanoparticle characterization, plasma retention, nanoparticle toxicity
MeSH terms
Animals, Blood-Brain Barrier, Central Nervous System Agents, Humans, Lipids, Drug Delivery Systems, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review